Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a prototype autoimmune disease mediated by type 1 helper T (TH1) cells and under the control of regulatory cells1,2,3. Here we report that a synthetic glycolipid ligand for CD1d-restricted natural killer T (NKT) cells expressing the semi-invariant T-cell receptor (Vα14+) is preventive against EAE. The ligand is an analogue of α-galactosylceramide (α-GC), a prototype NKT cell ligand, with a truncated sphingosine chain. α-GC causes NKT cells to produce both interferon (IFN)-γ and interleukin (IL)-4 (refs 4, 5). However, this new ligand can induce a predominant production of IL-4 by the NKT cells. A single injection of this glycolipid, but not of α-GC, consistently induced TH2 bias of autoimmune T cells by causing NKT cells to produce IL-4, leading to suppression of EAE. The lack of polymorphism of CD1d and cross-reactive response of mouse and human NKT cells to the same ligand6 indicates that targeting NKT cells with this ligand may be an attractive means for intervening in human autoimmune diseases such as multiple sclerosis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Structure and biological functions of α-GC and its analogues in vivo and in vitro.
Figure 2: Elevation of IgG1 isotype of anti-MOG35–55 antibody in the OCH-treated mice.
Figure 3: Serum cytokine kinetics after injection of different doses of α-GC.

References

  1. Nicholson, L. B. & Kuchroo, V. K. Manipulation of the Th1/Th2 balance in autoimmune disease. Curr. Opin. Immunol. 8, 837–842 (1996).

    Article  CAS  Google Scholar 

  2. Kumar, V., Aziz, F., Sercarz, E. & Miller, A. Regulatory T cells specific for the same framework 3 region of the Vβ8.2 chain are involved in the control of collagen II-induced arthritis and experimental autoimmune encephalomyelitis. J. Exp. Med. 185, 1725–1733 (1997).

    Article  CAS  PubMed Central  Google Scholar 

  3. Zhang, B-n., Yamamura, T., Kondo, T., Fujiwara, M. & Tabira, T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 186, 1677–1687 (1997).

    Article  CAS  PubMed Central  Google Scholar 

  4. Kawano, T. et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278, 1626–1629 (1997).

    Article  ADS  CAS  Google Scholar 

  5. Spada, F. M., Koezuka, Y. & Porcelli, S. A. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J. Exp. Med. 188, 1529–1534 (1998).

    Article  CAS  PubMed Central  Google Scholar 

  6. Brossay, L. et al. CD1d-mediated recognition of α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 188, 1521–1528 (1998).

    Article  CAS  PubMed Central  Google Scholar 

  7. Bix, M. & Locksley, R. M. Natural T cells. Cells that co-express NKRP-1 and TCR. J. Immunol. 155, 1020–1022 (1995).

    CAS  PubMed  Google Scholar 

  8. Bendelac, A., Rivera, M. N., Park, S. & Roark, J. H. Mouse CD1-specific NK1 T cells: development, specificity and function. Annu. Rev. Immunol. 15, 535–562 (1997).

    Article  CAS  Google Scholar 

  9. Godfrey, D. I., Hammond, K. J., Poulton, L. D., Smyth, M. J. & Baxter, A. G. NKT cells: Facts, functions and fallacies. Immunol. Today 21, 573–583 (2000).

    Article  CAS  Google Scholar 

  10. Matsuda, J. L. et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramer. J. Exp. Med. 192, 741–754 (2000).

    Article  CAS  PubMed Central  Google Scholar 

  11. Moody, D. B., Besra, G. S., Wilson, I. A. & Porcelli, S. A. The molecular basis of CD1-mediated presentation of lipid antigens. Immunol. Rev. 172, 285–296 (1999).

    Article  CAS  Google Scholar 

  12. Mieza, M. A. et al. Selective reduction of Vα14+NK T cells associated with disease development in autoimmune-prone mice. J. Immunol. 156, 4035–4040 (1996).

    CAS  PubMed  Google Scholar 

  13. Kirsten, J. L. et al. α/β T cell receptor (TCR)+ CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 187, 1047–1056 (1998).

    Article  Google Scholar 

  14. Sumida, T. et al. Selective reduction of T cells bearing invariant Vα24JαQ antigen receptor in patients with systemic sclerosis. J. Exp. Med. 182, 1163–1168 (1995).

    Article  CAS  Google Scholar 

  15. Wilson, S. B. et al. Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes. Nature 391, 177–181 (1998).

    Article  ADS  CAS  Google Scholar 

  16. Illés, Zs. et al. Differential expression of natural killer T cell Vα24JαQ invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J. Immunol. 164, 4375–4381 (2000).

    Article  Google Scholar 

  17. Pál, E. et al. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of Vα14 NK T cells. J. Immunol. 166, 662–668 (2001).

    Article  Google Scholar 

  18. Sloan-Lancaster, J. & Allen, P. M. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu. Rev. Immunol. 14, 1–27 (1996).

    Article  CAS  Google Scholar 

  19. Kappos, L. et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nature Med. 6, 1176–1182 (2000).

    Article  CAS  Google Scholar 

  20. Pedotti, R. et al. An unexpected version of horror autotoxicus: Anaphylactic shock to a self-peptide. Nature Immunol. 2, 216–222 (2001).

    Article  CAS  Google Scholar 

  21. Morita, M. et al. Synthesis of α-, β-monoglycosylceramides and four diastereomers of an α-galactosylceramide. Bioorg. Med. Chem. Lett. 5, 699–704 (1995).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank M. Taniguchi for supplying TCR Jα281-/- mice. This work was supported by a Research on Brain Science grant from the Ministry of Health, Labor and Welfare in Japan.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Takashi Yamamura.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miyamoto, K., Miyake, S. & Yamamura, T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413, 531–534 (2001). https://doi.org/10.1038/35097097

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/35097097

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing